BCV Asset Management’s Lexaria Bioscience LEXX Stock Holding History

BCV Asset Management’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-667	Closed	-$7.8K	–	121
2026 Q1	$7.8K	Buy	+667	New	+$7.26K	﹤0.01%	120

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCV Asset Management's LEXX Position: Q2 2026 in Review

BCV Asset Management sold out of Lexaria Bioscience (LEXX) in Q2 2026, closing a stake of 667 shares — an estimated $7.8K sold.

BCV Asset Management first reported a position in LEXX in Q1 2026 and held it in 1 quarter. The position peaked at $7.8K in Q1 2026. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

BCV Asset Management reported no remaining Lexaria Bioscience position as of Q2 2026 after selling out during the quarter.
BCV Asset Management sold 667 Lexaria Bioscience shares in Q2 2026, an estimated $7.8K.
BCV Asset Management first reported a position in Lexaria Bioscience in Q1 2026 and held it in 1 quarter.
BCV Asset Management's Lexaria Bioscience position peaked at $7.8K in Q1 2026.
29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on BCV Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.